Trial reportInflammation research : official journal of the European Histamine Research Society ... [et al.]2013
Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages.
Trial report in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00066027 (Low-Dose Doxycycline Effects on Osteopenic Bone Loss), which is not on this map. Cited by 6 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Low-Dose Doxycycline Effects on Osteopenic Bone Loss
Who cites it
6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.The Cochrane database of systematic reviews · 2022Pooled it
- Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.The Cochrane database of systematic reviews · 2019Pooled it
- Periodontal therapy for the management of cardiovascular disease in patients with chronic periodontitis.The Cochrane database of systematic reviews · 2017Pooled it
- High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacity Are Not Affected by Supervised Exercise but Are Associated with Baseline Interleukin-6 in Patients with Peripheral Artery Disease.Frontiers in cardiovascular medicine · 2017Article
- Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases.International dental journal · 2016Review
- Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities.The open dentistry journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
Abstract
objectiveSubantimicrobial-dose doxycycline (SDD) treatment has been reported to reduce the severity of chronic inflammation and to increase serum high-density lipoprotein cholesterol. In a double-blind, placebo-controlled clinical trial, we determined whether SDD affects the ability of serum to facilitate cholesterol removal from macrophages.
methodsForty-five postmenopausal osteopenic women with periodontitis were randomly assigned to take placebo (n = 26) or doxycycline hyclate (20 mg, n = 19) tablets twice daily for 2 years. Serum samples were collected at baseline, 1-, and 2-year appointments. The cholesterol efflux capacity of serum from cultured human macrophages (THP-1) was measured.
resultsSDD subjects demonstrated a significant increase in serum-mediated cholesterol efflux from macrophages at both time points compared to baseline (p < 0.04 for each). Mean cholesterol efflux levels over the first year of follow-up were 3.0 percentage points (unit change) higher among SDD subjects compared to placebo subjects (p = 0.010), while there was no significant difference in 2-year changes. There were no significant differences in the changes of apolipoprotein A-I, apolipoprotein A-II, or serum amyloid A levels between the groups.
conclusionsOur results suggest that SDD treatment may reduce the risk of cardiovascular disease in this patient group by increasing the cholesterol efflux capacity of serum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.